CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

Breast Cancer: Paving The Way For Personalized Combination Therapy

Breast Cancer: Paving The Way For Personalized Combination Therapy
Blog Posts

Breast Cancer: Paving the Way for Personalized Combination Therapy

The concept of ‘Personalized Medicine’ has gained momentum in oncology over the past decade, as progress made in molecular biology now enables more precise definition of the characteristics of individual patients. As the benefits of using of tumor profiling to support advanced treatment options such as targeted therapy and immunotherapy have become recognized, it is now apparent that use of combinations of drugs to target molecular aberrations is the next frontier in oncology.

Throughout the evolution of cancer treatment, one specific pathology has traditionally been on the leading edge: breast cancer. Today we once again find breast cancer to be in this position – as a pioneer for new advances in personalized combination therapy.

It all started in 1896, when the British surgeon George Beatson first described the stimulating effect of a female circulating substance (later called estrogen) on breast tumor development. His work provided a foundation for the modern use of anti-hormone therapy in oncology: in 1977, the breakthrough anti-estrogen tamoxifen (NOVALDEX®) was approved by the FDA for the treatment of advanced breast cancer. Simultaneously, several studies underlined the importance of estrogen receptor (ER) to better stratify patients who benefit from anti-estrogen therapies (i.e., patients with ER-positive tumors) from those who do not benefit and only suffer from unnecessary side effects of the drug (i.e., patients with ER-negative tumors). Today, the evaluation of ER expression level is a mandatory prerequisite for adequate management of breast cancer, and may therefore be considered as one of the first models for molecular-driven medicine.

Another important milestone in the care of breast cancer patients was the approval, in 1998, of the drug trastuzumab (HERCEPTIN®). Previous research showed that adding the monoclonal antibody to chemotherapy dramatically increases survival for women with advanced breast cancers in which a protein called Her-2 is over-produced.

Dysregulation of the cell cycle is a classic hallmark of cancer growth, and is largely observed in breast tumors. Therefore, re-establishing cell cycle control has emerged as an attractive option in the development of personalized therapy, and such molecules have shown extended response in newly diagnosed, as well as advanced and resistant, breast cancer patients.

While long considered individually, these three molecular drivers of breast oncogenesis (ER, Her2, and cell-cycle) may also be used together to suggest corresponding ‘a la carte’ drug combinations. Based on this concept, the FDA recently approved several therapeutic regimens that demonstrated superior safety and efficacy to monotherapies in breast cancer care. This approach has been shown to successfully overcome monotherapy drug resistances in other diseases such as HIV. A summary of combinations acknowledged by the FDA for the care of breast cancer is provided in the table below:

 

THERAPEUTIC REGIMENS APPROVED BY THE FDA FOR THE TREATMENT OF BREAST CANCER

A patient presenting a tumor that isWill benefit from:
ER-positive, Her2-positivea combination of anti-estrogen and Her2 blocker[1]

letrozole (FEMARA®) and lapatinib (TYKERB®)

ER-positive, Her2-negative
with cell-cycle altereda combination of anti-estrogen and cell-cycle blocker

letrozole (FEMARA®) and palbociclib (IBRANCE®)

fulvestrant (FASLODEX®) and palbociclib (IBRANCE®)

letrozole (FEMARA®) and ribociclib (KISQALI®)

with cell-cycle unalteredan anti-estrogen alone
ER-negative, Her2-positivea Her-2 blocker alone[2]

 

The remaining category of tumors – tumors that are negative for both estrogen and Her2 receptors (not shown in the table) – concerns 15 to 20% of all diagnosed breast cancers and is still considered to be a therapeutic challenge. However, this heterogeneous subgroup is composed of at least 4 to 6 definable molecular subtypes that may be sensitive to treatments targeting other cellular processes, such as PARP (poly ADP-ribose polymerase) inhibitors, VEGF (vascular endothelial growth factor) inhibitors, or EGFR (epidermal growth factor receptor) inhibitors, as well as suitable cytotoxic chemotherapy. These subtypes of breast cancers are therefore prime candidates for the development of new personalized combination therapy options, and are under investigation for what is seen as the ultimate ‘Holy Grail’ in breast cancer research.

Overall, the advances in therapeutic management of breast cancer demonstrate how, by using a limited set of pharmacology classes and associating them in a ‘mix-and-match’ combination by taking into account the molecular fingerprint of each patient, health care specialists have managed to proficiently improve patient outcomes. Just as breast cancer has served as a proving ground for new treatment options in the past, we expect these positive results to pave the way for broader use of personalized combination therapies throughout oncology.

-Amelie Boichard, Ph.D.

 

“Metastatic Breast Cancer in Pleural Fluid” flickr photo by Ed Uthman shared under a Creative Commons License.

 

[1] Several phase II clinical trials studying the benefit of a combination of an anti-estrogen with a Her2 blocker and a cell-cycle blocker are currently in progress for patients carrying an ER-positive / Her2-positive / cell-cycle altered tumor.

[2] Several phase II clinical trials studying the benefit of a combination of a Her2 blocker with a cell-cycle blocker are currently in progress for patients carrying an ER-negative / Her2-positive /cell-cycle altered tumor.

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data